Safety Study of Dexmedetomidine in Elderly Under General Anesthesia
Hip Fractures, Hip Disease
About this trial
This is an interventional supportive care trial for Hip Fractures focused on measuring Dexmedetomidine, Elderly, Hemodynamics, Hip replacement, General anesthesia
Eligibility Criteria
Inclusion Criteria:
- age ≥65yr, American Society of Anesthesiologists (ASA) physical status scale grade I-III, ready for HP; body weight between 45 and 75kg, body mass index (BMI) between 18 and 24kg/m2;
- the health conditions generally well according to medical history, physical examination, and laboratory tests;
- no signs of difficult intubation;
- no history of dementia and mental problems;
- normal cognitive function, ability to understand and comply with study procedures.
Exclusion Criteria:
- Age <65 yr or >90 yr; BMI greater than 24 kg/m2; ASA grade higher than III;
- Heart failure, severe arrhythmias, severe bradycardia (heart rate less than 40 beats/min), atrioventricular block of degree 2 or above, sick sinus syndrome, systolic blood pressure (SBP) ≥180 or <90 mmHg, diastolic blood pressure (DBP) ≥110 or <60 mmHg;
- Severe liver or kidney dysfunction, severe infection, and other pathological conditions that interfere with study results.
- Dementia, cerebrovascular accidents within 3 months, mental illness, epilepsy, and other adverse events that interfere with study results.
- Patients with the conditions that block communication and preoperative assessment, such as serious hearing or visual impairment;
- History of chronic analgesic use, long-term psychotropic medication use, alcohol or drug addiction.
Sites / Locations
- Zhenjiang First People's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Group D0.25, Group D0.5, Group D0.75
Group NS, Group MD
Dexmedetomidine will be administered at different initial loading doses (0.25/0.5/0.75 μg/kg within 15min) following same maintained dosage ( 0.5μg/kg/h) in Group D0.25/D0.5/D0.75.
In Group NS, patients will be pumped 0.1ml/kg of normal saline for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation. In Group MD, patients will be administrated with midazolam 0.03mg/kg at the beginning of anesthesia induction.